Nevro (NVRO) Stock Price, News & Analysis

Company Overview

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $5.84 to $5.86
• 50-Day Range: $5.85 to $5.85
• 52-Week Range: $3.17 to $10.34
• Volume: 753,602 shs
• Average Volume: 818,428 shs
• Market Capitalization: $224.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.36
• Consensus Rating: Reduce

NVRO Stock Analysis - Frequently Asked Questions

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) released its earnings results on Tuesday, March, 4th. The medical equipment provider reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.15. The medical equipment provider had revenue of $105.55 million for the quarter, compared to analyst estimates of $102.61 million. Nevro had a negative trailing twelve-month return on equity of 23.52% and a negative net margin of 16.54%.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nevro investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 3/04/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NVRO
• CIK: 1444380
• Web: www.nevro.com
• Phone: (650) 251-0005
• Fax: N/A
• Employees: 1,090
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nevro: $5.36
• High Price Target: $7.00
• Low Price Target: $4.00
• Potential Upside/Downside: -8.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$92.21 million
• Net Margins: -16.54%
• Pretax Margin: -17.89%
• Return on Equity: -23.52%
• Return on Assets: -10.83%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 5.02
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $408.52 million
• Price / Sales: 0.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.10 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 38,372,000
• Free Float: 36,273,000
• Market Cap: $224.32 million
• Optionable: Optionable
• Beta: 0.81